Protagonist Therapeutics (PTGX) to Release Earnings on Wednesday

Protagonist Therapeutics (NASDAQ:PTGX) is expected to be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of $2.23 per share and revenue of $199.8120 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.55. The business had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. On average, analysts expect Protagonist Therapeutics to post $4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $136.64 on Monday. The company has a market capitalization of $8.79 billion, a PE ratio of -75.49 and a beta of 1.79. Protagonist Therapeutics has a 12 month low of $50.49 and a 12 month high of $143.29. The stock’s 50-day moving average price is $120.38 and its two-hundred day moving average price is $103.39.

Insiders Place Their Bets

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the completion of the sale, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $52,410,617.36. This trade represents a 12.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bryan Giraudo sold 6,000 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $100.00, for a total value of $600,000.00. Following the completion of the transaction, the director directly owned 31,825 shares in the company, valued at $3,182,500. This represents a 15.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 161,130 shares of company stock worth $16,355,220. Company insiders own 5.19% of the company’s stock.

Hedge Funds Weigh In On Protagonist Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PTGX. Greenline Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter worth approximately $27,000. Osaic Holdings Inc. lifted its position in shares of Protagonist Therapeutics by 79.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after acquiring an additional 525 shares during the period. Quadrant Capital Group LLC bought a new position in Protagonist Therapeutics during the third quarter worth $90,000. Truvestments Capital LLC boosted its stake in Protagonist Therapeutics by 60.8% during the fourth quarter. Truvestments Capital LLC now owns 1,161 shares of the company’s stock worth $101,000 after acquiring an additional 439 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Protagonist Therapeutics by 23.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,727 shares of the company’s stock worth $151,000 after acquiring an additional 324 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wedbush raised their price objective on Protagonist Therapeutics from $112.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Wolfe Research began coverage on Protagonist Therapeutics in a report on Thursday, May 21st. They issued an “outperform” rating and a $135.00 target price on the stock. Zacks Research raised shares of Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $110.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $123.00.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.